Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at Chardan Capital

Tenaya Therapeutics (NASDAQ:TNYA)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $9.00 target price on the stock.

TNYA has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Tenaya Therapeutics in a research note on Tuesday, September 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Tenaya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Tenaya Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $6.25.

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics stock traded up $0.19 during mid-day trading on Monday, reaching $1.47. The company’s stock had a trading volume of 5,498,944 shares, compared to its average volume of 3,242,607. Tenaya Therapeutics has a 12 month low of $0.36 and a 12 month high of $4.01. The business’s 50 day simple moving average is $1.53 and its 200 day simple moving average is $0.97. The company has a market capitalization of $238.77 million, a price-to-earnings ratio of -1.53 and a beta of 3.14.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03. As a group, sell-side analysts expect that Tenaya Therapeutics will post -1.35 EPS for the current year.

Hedge Funds Weigh In On Tenaya Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Nuveen LLC bought a new position in shares of Tenaya Therapeutics in the first quarter worth about $129,000. Ieq Capital LLC acquired a new position in Tenaya Therapeutics during the 1st quarter worth about $95,000. DAFNA Capital Management LLC acquired a new stake in Tenaya Therapeutics during the 1st quarter valued at approximately $27,000. Virtu Financial LLC increased its position in Tenaya Therapeutics by 29.4% during the 1st quarter. Virtu Financial LLC now owns 135,502 shares of the company’s stock valued at $77,000 after purchasing an additional 30,790 shares during the period. Finally, CWM LLC boosted its position in Tenaya Therapeutics by 14,231.7% during the first quarter. CWM LLC now owns 71,945 shares of the company’s stock valued at $41,000 after acquiring an additional 71,443 shares during the last quarter. Institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.